 |
|
Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways
Seung Min Lee, Dong Hee Koh, Dae Won Jun, Yoon Jin Roh, Hyeon Tae Kang, Ju Hee Oh, Hyun Sung Kim
Clin Mol Hepatol. 2022;28(4):827-840. Published online 2022 Jun 22 DOI: https://doi.org/10.3350/cmh.2022.0068
|
|
Citations to this article as recorded by
 Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”
Yuanbin Liu, Mingkai Chen
Clinical and Molecular Hepatology.2023; 29(1): 163. CrossRef Oleoylethanolamide alleviates hyperlipidaemia-mediated vascular calcification via attenuating mitochondrial DNA stress triggered autophagy-dependent ferroptosis by activating PPARα
Zhengdong Chen, Xuejiao Sun, Xiaoxue Li, Naifeng Liu
Biochemical Pharmacology.2023; 208: 115379. CrossRef Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response
Silvia Sookoian, Carlos J. Pirola
Clinical and Molecular Hepatology.2023; 29(Suppl): S184. CrossRef Repurposing drugs to target nonalcoholic steatohepatitis: Auranofin, a gold-organic molecule complex for the treatment of a specifc complex trait
Carlos J. Pirola, Silvia Sookoian
Clinical and Molecular Hepatology.2022; 28(4): 806. CrossRef
|